Predictive Oncology Future Growth
Future criteria checks 5/6
Predictive Oncology is forecast to grow earnings and revenue by 74.6% and 52.7% per annum respectively while EPS is expected to grow by 74% per annum.
Key information
74.6%
Earnings growth rate
74.0%
EPS growth rate
| Medical Equipment earnings growth | 14.2% |
| Revenue growth rate | 52.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15 | 2 | N/A | N/A | 1 |
| 12/31/2025 | 9 | -2 | N/A | N/A | 1 |
| 12/31/2024 | 1 | -11 | N/A | N/A | 1 |
| 9/30/2024 | 1 | -14 | -13 | -13 | N/A |
| 6/30/2024 | 2 | -14 | -13 | -13 | N/A |
| 3/31/2024 | 2 | -15 | -13 | -13 | N/A |
| 12/31/2023 | 2 | -14 | -13 | -13 | N/A |
| 9/30/2023 | 2 | -17 | -13 | -13 | N/A |
| 6/30/2023 | 2 | -19 | -13 | -13 | N/A |
| 3/31/2023 | 1 | -26 | -13 | -13 | N/A |
| 12/31/2022 | 2 | -26 | -13 | -12 | N/A |
| 9/30/2022 | 2 | -26 | -13 | -13 | N/A |
| 6/30/2022 | 1 | -27 | -14 | -13 | N/A |
| 3/31/2022 | 1 | -19 | -13 | -12 | N/A |
| 12/31/2021 | 1 | -20 | -13 | -12 | N/A |
| 9/30/2021 | 1 | -23 | -12 | -11 | N/A |
| 6/30/2021 | 1 | -25 | -12 | -11 | N/A |
| 3/31/2021 | 1 | -26 | -13 | -13 | N/A |
| 12/31/2020 | 1 | -26 | -13 | -12 | N/A |
| 9/30/2020 | 1 | -29 | -13 | -13 | N/A |
| 6/30/2020 | 1 | -26 | -11 | -11 | N/A |
| 3/31/2020 | 1 | -21 | -10 | -10 | N/A |
| 12/31/2019 | 1 | -20 | -9 | -9 | N/A |
| 9/30/2019 | 1 | -9 | -7 | -7 | N/A |
| 6/30/2019 | 1 | -8 | -6 | -6 | N/A |
| 3/31/2019 | 1 | -12 | -6 | -6 | N/A |
| 12/31/2018 | 1 | -10 | -6 | -5 | N/A |
| 9/30/2018 | 1 | -8 | -6 | -5 | N/A |
| 6/30/2018 | 1 | -6 | N/A | -5 | N/A |
| 3/31/2018 | 1 | -6 | N/A | -5 | N/A |
| 12/31/2017 | 1 | -6 | N/A | -4 | N/A |
| 9/30/2017 | 1 | -6 | N/A | -4 | N/A |
| 6/30/2017 | 1 | -6 | N/A | -4 | N/A |
| 3/31/2017 | 1 | -6 | N/A | -4 | N/A |
| 12/31/2016 | 0 | -7 | N/A | -4 | N/A |
| 9/30/2016 | 1 | -8 | N/A | -7 | N/A |
| 6/30/2016 | 0 | -8 | N/A | -10 | N/A |
| 3/31/2016 | 1 | -7 | N/A | -9 | N/A |
| 12/31/2015 | 1 | -5 | N/A | -7 | N/A |
| 9/30/2015 | 1 | -5 | N/A | -5 | N/A |
| 6/30/2015 | 1 | -5 | N/A | -2 | N/A |
| 3/31/2015 | 1 | -5 | N/A | -2 | N/A |
| 12/31/2014 | 1 | -7 | N/A | -3 | N/A |
| 9/30/2014 | 1 | -7 | N/A | -4 | N/A |
| 6/30/2014 | 1 | -9 | N/A | -4 | N/A |
| 3/31/2014 | 0 | -9 | N/A | -5 | N/A |
| 12/31/2013 | 0 | -9 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: S1K is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: S1K is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: S1K is expected to become profitable in the next 3 years.
Revenue vs Market: S1K's revenue (52.7% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: S1K's revenue (52.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if S1K's Return on Equity is forecast to be high in 3 years time